Given that various molecular categories are likely more common in different geographic regions (e.g., EBV is endemic in certain regions), and various MET-targeting agents may be more efficacious against some MET abnormalities than others (e.g., a MET TKI may be more efficacious than an agent targeting the extracellular MET receptor domain in the case of MET autophosphorylation), these factors now have to be considered when developing a MET-targeting agent for gastric cancer. This evidence concerns the gene MET and gastric cancer.